Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Phase 3 Study of SGX301 and Fluorescent Light for Cutaneous T Cell Lymphoma

Award Number: R44CA210848
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/14/2017
PERIOD OF PERFORMANCE END DATE: 01/31/2020

Group Awards By:

View Award Description

Phase 3 Study of SGX301 and Fluorescent Light for Cutaneous T Cell Lymphoma - 7. Project Summary/Abstract (changes are in Time New Roman font) Cutaneous T-cell lymphoma (CTCL) is a rare form of Non-Hodgkin's Lymphoma (NHL) affecting approximately 21,000 patients annually in the United States and can be characterized by either an indolent or aggressive disease progression. Either case is accompanied by significant morbidity, particularly due to the skin effects of the disease. The indolent disease may eventually progress to a more aggressive systemic disease associated with significant mortality. When the disease is primarily localized to the skin it is referred to as mycosis fungoides (MF) and is characterized by abnormal accumulation of T-cells in the skin, causing lesions, which increasingly cover the body as the disease progresses. These lesions can be scaly patches of varying color and/or eczema like-rashes and/or psoriasis-like rashes. Thick tumors may develop on the skin that may eventually become open, infected ulcers. The lesions are often associated with severe itching, making sleep and other daily activities difficult. Early treatment of MF can prevent progression to the open ulcerative skin tumor stage. CTCL is an orphan disease with no approved first-line therapy. The active pharmaceutical ingredient of Soligenix's SGX301 technology is synthetic hypericin, a photo-activated agent that intracellularly concentrates in the endoplasmic reticulum and, with activation by visible light, generates singlet oxygen that causes localized reactive-oxygen species that initiates the mitochondrial apoptotic pathway Because of its lack of DNA interactions and negative Ames test, it is anticipated that this treatment will have a substantially lower risk for secondary cancer development than the majority of CTCL treatments that, because their anti-tumor effects are generated through DNA damage mechanisms, have either theoretical or proven long-term association with secondary cancers including melanoma. Importantly, hypericin is not by itself mutagenic, like other treatments, and is activated by visible light, which is not carcinogenic. The two components can be easily combined at the site of a skin lesion, resulting in highly selective delivery and killing of tumor cells with minimal systemic impact on the patient. Phase 1 and 2 clinical studies have clearly demonstrated its safety and efficacy, including a patient response rate >50% with hypericin treatment (0.1% or 0.25%). SGX301 has been granted Fast Track Designation by the US FDA for the first line treatment of CTCL and hypericin has been granted Orphan Product Designation for the treatment of CTCL (Designation #99-1310). This proposal seeks to conduct a Phase 3 registration trial, HPN-CTCL-01, evaluating the safety and efficacy of 0.25% hypericin in the treatment of CTCL. The Specific Aims of this proposal are: 1) Test the hypothesis that in patients with early stage cutaneous T-cell Lymphoma (CTCL), topically applied hypericin in association with standard fluorescent bulb light phototherapy given twice per week for 6 weeks can induce a clinically meaningful improvement in skin lesions when compared to placebo therapy; and 2) Assess the utility of repeat treatments of hypericin in early stage CTCL.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2018	SOLIGENIX, INC.	29 EMMONS DR STE B10	PRINCETON	NJ	08540	MERCER	USA	Cancer Treatment Research	000	2	6/16/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2018 ( Subtotal = $750,000 )
2018	2018	SOLIGENIX, INC.	29 EMMONS DR STE B10	PRINCETON	NJ	08540	MERCER	USA	Cancer Treatment Research	000	2	8/24/2018	NON-COMPETING CONTINUATION	$750,000
														Subtotal = $750,000

Issue Date FY: 2017 ( Subtotal = $750,000 )
2017	2017	SOLIGENIX, INC.	29 EMMONS DR STE C10	PRINCETON	NJ	08540	MERCER	USA	Cancer Treatment Research	000	1	9/14/2017	NEW	$750,000
														Subtotal = $750,000

Grand Total All Awards = $1,500,000

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Phase 3 Study of SGX301 and Fluorescent Light for Cutaneous T Cell Lymphoma

Award Number: R44CA210848

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/14/2017

PERIOD OF PERFORMANCE END DATE: 01/31/2020

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer